Comparison · GLP-1
Ozempic vs Mounjaro · The Diabetes Labels Compared
Same molecules as Wegovy and Zepbound, different label, different dose. A physician guide to how the diabetes brands stack up.
Ozempic and Mounjaro are the type 2 diabetes labels for the two molecules that have changed obesity medicine · semaglutide and tirzepatide. Wegovy is the same molecule as Ozempic at a higher dose for weight management. Zepbound is the same molecule as Mounjaro at the same doses for weight management. The split-label structure is a regulatory artifact, not a clinical one · the molecules behave the same in your body whether the box says Ozempic or Wegovy, Mounjaro or Zepbound.
That overlap is why patients without diabetes sometimes ask whether they can use the diabetes label off-label for weight loss. Sometimes they do. The honest answer is that off-label use of Ozempic or Mounjaro for weight management is common, sometimes covered by insurance, and clinically reasonable in selected cases · but the FDA-approved path for weight management is Wegovy or Zepbound, and the labeled doses are the doses studied for weight outcomes.
This page compares Ozempic and Mounjaro head-to-head on the diabetes outcomes they were studied for, the weight loss they produce as a side effect of glycemic control, and the practical considerations that drive the choice between them.
Ozempic vs Mounjaro · at a glance
| Ozempic (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Active molecule | Semaglutide | Tirzepatide |
| Receptor activity | GLP-1 agonist | GLP-1 and GIP dual agonist |
| FDA-approved indication | Type 2 diabetes, cardiovascular risk reduction | Type 2 diabetes |
| Weight-management label sister product | Wegovy | Zepbound |
| Diabetes maintenance dose | 0.5, 1, or 2 mg weekly | 5, 10, or 15 mg weekly |
| Average A1c reduction | 1.4 to 1.8 percent | 1.9 to 2.4 percent |
| Average weight loss in diabetes trials | About 6 to 12 pounds | About 12 to 25 pounds |
| List price (cash, monthly) | About 970 USD | About 1,070 USD |
Same molecules, different labels · why it matters
The FDA approves a drug for an indication based on the trials the manufacturer ran. Novo Nordisk ran one set of trials at lower doses for diabetes (Ozempic) and another set at a higher dose for weight management (Wegovy). Eli Lilly did the same with Mounjaro for diabetes and Zepbound for weight management. The molecule is identical. The branding, packaging, and approved use are different.
From an insurance and prior-authorization standpoint, the split matters a lot. Diabetes coverage is more widespread than weight-management coverage. A patient with type 2 diabetes whose A1c is above target will usually find Ozempic or Mounjaro covered. The same patient trying to get Wegovy or Zepbound for weight management without a diabetes diagnosis will often face denial, prior-authorization friction, or a high copay.
From a clinical standpoint, the molecules act the same way at the same dose regardless of label. A patient on Ozempic 1 mg gets the same drug at the same dose as a patient on Wegovy 1 mg. The Wegovy label simply allows higher maintenance doses (2.4 mg) that the Ozempic label does not include.
A1c and diabetes outcomes
Both Ozempic and Mounjaro are first-line injectable add-ons in modern type 2 diabetes care after metformin. Both lower A1c, lower fasting glucose, and reduce post-meal glucose spikes. Both have been compared head-to-head and tirzepatide consistently produced larger reductions.
In SURPASS-2, a 40-week trial in adults with type 2 diabetes inadequately controlled on metformin, tirzepatide reduced A1c by 2.0, 2.2, and 2.3 percentage points at the 5, 10, and 15 mg doses respectively, compared with 1.9 percentage points for semaglutide 1 mg. Tirzepatide also produced larger weight loss at every dose level.
Ozempic has the longer cardiovascular outcomes track record. SUSTAIN-6 showed a 26 percent reduction in major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. The SELECT trial extended the cardiovascular benefit to non-diabetic patients with overweight or obesity and prior cardiovascular disease. Mounjaro is still accumulating long-term cardiovascular outcome data · the SURPASS-CVOT trial is ongoing.
Weight loss as a side effect of glycemic control
Both medications produce meaningful weight loss in their diabetes trials, even though weight loss was a secondary endpoint and the doses studied were lower than the weight-management doses. Ozempic at 1 mg produced about 9 pounds of average weight loss over a year in SUSTAIN trials. Mounjaro at 15 mg produced about 25 pounds in SURPASS-2.
Patients without diabetes sometimes use Ozempic or Mounjaro off-label for weight loss when their insurance does not cover Wegovy or Zepbound but does cover the diabetes label. Off-label prescribing is legal and common in medicine generally · the practical issue is that the dose ladders on Ozempic and Mounjaro top out at lower doses than the weight-management labels, so the maximum weight loss achievable is somewhat lower.
Body Good Studio prescribes the FDA-approved label for the indication when possible. Wegovy or Zepbound for weight management. Ozempic or Mounjaro for type 2 diabetes. We do not generally use diabetes labels off-label as a workaround for weight-management coverage decisions · we work with the patient on the appropriate label or on a compounded option.
Side effects and tolerability
Side-effect profiles mirror the molecule. Ozempic produces the same GLP-1 family of GI effects as Wegovy · nausea, fullness, reflux, constipation. Mounjaro produces the same GLP-1 plus GIP profile as Zepbound · nausea, diarrhea early in titration, decreased appetite. Diabetes-dose Ozempic and Mounjaro are usually better tolerated than the higher weight-management doses simply because the dose is lower.
Both carry boxed warnings about thyroid C-cell tumors based on rodent data and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. Both have rare associations with pancreatitis and gallbladder disease. Pancreatitis risk is higher in patients with a history of gallstones or alcohol use disorder.
Hypoglycemia is rare with either medication as monotherapy because the insulin secretion is glucose-dependent. The risk increases when used with sulfonylureas or insulin · in those combinations, dose adjustments to the background diabetes regimen are usually needed.
How to choose between them
If you have type 2 diabetes and need an injectable add-on after metformin, the choice between Ozempic and Mounjaro comes down to A1c reduction needed, weight goal, cardiovascular risk profile, and insurance coverage. Patients who need substantial A1c reduction and weight loss generally do better on Mounjaro. Patients with established cardiovascular disease and a need for proven cardiovascular outcome data may benefit from the longer Ozempic track record.
If you do not have diabetes and you are looking at these medications for weight management, the answer is to use the weight-management label · Wegovy or Zepbound · not the diabetes label. The doses on the weight-management labels are higher, the indication is FDA approved for your situation, and the trial data is direct. We compare those two in our Wegovy vs Zepbound guide.
If you have diabetes and a high BMI, both indications apply and either label is reasonable. The deciding factor in our practice is usually whichever your insurance covers at the lowest copay · the molecule is what produces the result, and any of these four labels is a clinically defensible starting point.
Frequently asked questions
Are Ozempic and Wegovy the same drug?
Same molecule, different label and different doses. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. The molecule is semaglutide in both.
Are Mounjaro and Zepbound the same drug?
Yes, same molecule (tirzepatide) and same dose ladder (5, 10, 15 mg weekly). Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The active product is identical.
Can I use Ozempic for weight loss without diabetes?
It is sometimes prescribed off-label for weight loss when Wegovy is not accessible. Off-label prescribing is legal but the FDA-approved path for weight management is Wegovy. We typically prefer the labeled product or a compounded alternative rather than diabetes-label workarounds.
Which one lowers A1c more?
Mounjaro produced larger A1c reductions than Ozempic in the SURPASS-2 head-to-head trial. Both are highly effective. The choice depends on starting A1c, weight goal, cardiovascular history, and insurance coverage.
See if a GLP-1 is the right next step
The two-minute quiz reviews your weight goal, diabetes status, insurance, and side-effect tolerance, then recommends the appropriate label or compounded option.
This page is educational and is not a substitute for medical advice. Ozempic and Mounjaro are prescription medications approved for type 2 diabetes. Off-label use is at the discretion of the prescribing clinician.